@article{3020576, title = "Expression of syndecan-1 in chronic liver diseases: Correlation with hepatic fibrosis", author = "Charchanti, A. and Kanavaros, P. and Koniaris, E. and Kataki, A. and Glantzounis, G. and Agnantis, N.J. and Goussia, A.C.", journal = "In vivo (Athens, Greece)", year = "2021", volume = "35", number = "1", pages = "333-339", publisher = "International Institute of Anticancer Research", doi = "10.21873/INVIVO.12264", keywords = "syndecan 1; membrane protein; syndecan 1, adolescent; adult; aged; Article; chronic liver disease; controlled study; correlation analysis; female; fibrogenesis; human; human tissue; immunohistochemistry; liver biopsy; liver fibrosis; major clinical study; male; pathogenesis; protein expression; staging; tissue section; very elderly; genetics; immunohistochemistry; liver cirrhosis, Humans; Immunohistochemistry; Liver Cirrhosis; Membrane Glycoproteins; Syndecan-1", abstract = "Background/Aim: The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis. Materials and Methods: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated. Results: According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis. Conclusion: In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis. © 2021 International Institute of Anticancer Research. All rights reserved." }